 |
|
Treatment of Stage IA Cutaneous T-Cell Lymphoma With Topical Application of the Immune Response Modifier Imiquimod
Karen Rebecca Suchin, MD;
Jacqueline M. Junkins-Hopkins, MD;
Alain H. Rook, MD;
Hospital of the University of Pennsylvania, Philadelphia
Arch Dermatol. 2002;138:1137-1139.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
REPORT OF A CASE
A 52-year-old woman with cutaneous T-cell lymphoma (CTCL) presented
to the dermatology clinic for treatment. She had a more than 10-year history
of episodic dry, itchy patches over her trunk and extremities. Previous biopsy
specimens obtained from the patches revealed histopathologic changes typical
of CTCL. Treatment with a number of topical steroid preparations and topical
nitrogen mustard and carmustine had been ineffective. On physical examination,
she had 2 clinically similar, well-demarcated patches with mild erythema and
scale involving less than 10% of her total body surface area (stage IA). She
had no evidence of systemic involvement.
THERAPEUTIC CHALLENGE
Although patients with stage IA CTLC (less than 10% total skin surface
involvement without lymph node or visceral metastases) experience long-term
survival similar to that of a matched control population, approximately 10%
progress to more . . . [Full Text of this Article]
SOLUTION
COMMENT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Imiquimod Treatment of Exuberant Granulation Tissue in a Nonhealing Diabetic Ulcer
Lain and Carrington
Arch Dermatol 2005;141:1368-1370.
FULL TEXT
Imiquimod: A Topically Applied Link Between Innate and Acquired Immunity
Hurwitz et al.
Arch Dermatol 2003;139:1347-1350.
FULL TEXT
|
